Active, Not Recruiting
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
NCT03999749
- Conditions
- Melanoma, Neoplasms, Neoplasms by Histologic Type, +9 more
- Locations
-
- The Angeles Clinic Los Angeles, California, United States
- Massachusetts General Hospital Boston, Massachusetts, United States
- Dana Farber Cancer Institute Boston, Massachusetts, United States
- NYU Langone Health New York, United States